Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13588
UPID:
GRAP_HUMAN
Alternative names:
-
Alternative UPACC:
Q13588
Background:
The GRB2-related adapter protein plays a pivotal role in transmitting signals from receptor and cytoplasmic tyrosine kinases to the Ras signaling pathway. Its involvement is crucial for the proper functioning of the inner ear, directly impacting hearing capabilities as evidenced by research findings (PubMed:30610177).
Therapeutic significance:
Linked to Deafness, autosomal recessive, 114, a condition characterized by congenital profound sensorineural hearing loss, the GRB2-related adapter protein's genetic variants offer a promising target for therapeutic intervention. Understanding its role could pave the way for innovative treatments.